222 related articles for article (PubMed ID: 23413263)
1. Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells.
Doddrell RD; Dun XP; Shivane A; Feltri ML; Wrabetz L; Wegner M; Sock E; Hanemann CO; Parkinson DB
Brain; 2013 Feb; 136(Pt 2):549-63. PubMed ID: 23413263
[TBL] [Abstract][Full Text] [Related]
2. Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells.
Flaiz C; Utermark T; Parkinson DB; Poetsch A; Hanemann CO
Glia; 2008 Apr; 56(5):506-15. PubMed ID: 18240308
[TBL] [Abstract][Full Text] [Related]
3. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
4. Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma.
Flaiz C; Ammoun S; Biebl A; Hanemann CO
Brain Pathol; 2009 Jan; 19(1):27-38. PubMed ID: 18445079
[TBL] [Abstract][Full Text] [Related]
5. Cellular prion protein (PrP
Provenzano L; Ryan Y; Hilton DA; Lyons-Rimmer J; Dave F; Maze EA; Adams CL; Rigby-Jones R; Ammoun S; Hanemann CO
Oncogene; 2017 Nov; 36(44):6132-6142. PubMed ID: 28692055
[TBL] [Abstract][Full Text] [Related]
6. Activation of Krox20 gene expression by Sox10 in myelinating Schwann cells.
Reiprich S; Kriesch J; Schreiner S; Wegner M
J Neurochem; 2010 Feb; 112(3):744-54. PubMed ID: 19922439
[TBL] [Abstract][Full Text] [Related]
7. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
8. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
9. Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.
Bassiri K; Ferluga S; Sharma V; Syed N; Adams CL; Lasonder E; Hanemann CO
EBioMedicine; 2017 Feb; 16():76-86. PubMed ID: 28126595
[TBL] [Abstract][Full Text] [Related]
10. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM; Garcia J; Bott M; Klingeman Plati S; Dinh CT; Bracho OR; Yan D; Zou B; Mittal R; Telischi FF; Liu XZ; Chang LS; Welling DB; Copik AJ; Fernández-Valle C
Oncotarget; 2017 May; 8(19):31666-31681. PubMed ID: 28427224
[TBL] [Abstract][Full Text] [Related]
11. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis.
Schulze KM; Hanemann CO; Müller HW; Hanenberg H
Hum Mol Genet; 2002 Jan; 11(1):69-76. PubMed ID: 11773000
[TBL] [Abstract][Full Text] [Related]
12. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells.
Bashour AM; Meng JJ; Ip W; MacCollin M; Ratner N
Mol Cell Biol; 2002 Feb; 22(4):1150-7. PubMed ID: 11809806
[TBL] [Abstract][Full Text] [Related]
13. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
[TBL] [Abstract][Full Text] [Related]
14. Generation and Use of Merlin-Deficient Human Schwann Cells for a High-Throughput Chemical Genomics Screening Assay.
Petrilli AM; Fernández-Valle C
Methods Mol Biol; 2018; 1739():161-173. PubMed ID: 29546707
[TBL] [Abstract][Full Text] [Related]
15. RKIP Induction Promotes Tumor Differentiation via SOX2 Degradation in NF2-Deficient Conditions.
Cho JH; Park S; Kim S; Kang SM; Woo TG; Yoon MH; Lee H; Jeong M; Park YH; Kim H; Han YT; Suh YG; Kim BH; Kwon Y; Yun H; Park BJ
Mol Cancer Res; 2022 Mar; 20(3):412-424. PubMed ID: 34728553
[TBL] [Abstract][Full Text] [Related]
16. Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism.
Wong HK; Shimizu A; Kirkpatrick ND; Garkavtsev I; Chan AW; di Tomaso E; Klagsbrun M; Jain RK
Neoplasia; 2012 Feb; 14(2):84-94. PubMed ID: 22431917
[TBL] [Abstract][Full Text] [Related]
17. A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
Gehlhausen JR; Hawley E; Wahle BM; He Y; Edwards D; Rhodes SD; Lajiness JD; Staser K; Chen S; Yang X; Yuan J; Li X; Jiang L; Smith A; Bessler W; Sandusky G; Stemmer-Rachamimov A; Stuhlmiller TJ; Angus SP; Johnson GL; Nalepa G; Yates CW; Wade Clapp D; Park SJ
Hum Mol Genet; 2019 Feb; 28(4):572-583. PubMed ID: 30335132
[TBL] [Abstract][Full Text] [Related]
18. SWI/SNF enzymes promote SOX10- mediated activation of myelin gene expression.
Marathe HG; Mehta G; Zhang X; Datar I; Mehrotra A; Yeung KC; de la Serna IL
PLoS One; 2013; 8(7):e69037. PubMed ID: 23874858
[TBL] [Abstract][Full Text] [Related]
19. Functional dissection of the Oct6 Schwann cell enhancer reveals an essential role for dimeric Sox10 binding.
Jagalur NB; Ghazvini M; Mandemakers W; Driegen S; Maas A; Jones EA; Jaegle M; Grosveld F; Svaren J; Meijer D
J Neurosci; 2011 Jun; 31(23):8585-94. PubMed ID: 21653862
[TBL] [Abstract][Full Text] [Related]
20. Sox10 is required for Schwann-cell homeostasis and myelin maintenance in the adult peripheral nerve.
Bremer M; Fröb F; Kichko T; Reeh P; Tamm ER; Suter U; Wegner M
Glia; 2011 Jul; 59(7):1022-32. PubMed ID: 21491499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
